Old Web
English
Sign In
Acemap
>
authorDetail
>
I. Katay
I. Katay
Cancer research
Pathology
Medicine
Sorafenib
Everolimus
5
Papers
2
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (5)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
The combination of sorafenib and everolimus in patients with solid tumors: Results of a phase I study.
2011
Journal of Clinical Oncology
Lucia Nogova
Christian Mattonet
Matthias Scheffler
Irini Papachristou
N. Muthen
Martin L. Sos
U. T. Hacker
Thomas Elter
Heiko Backes
Carsten Kobe
Kerstin Rhiem
P Mallmann
Uwe Fuhr
Roland Schnell
I. Katay
Karin Toepelt
Marcel Reiser
Nadia Harbeck
Markus Dietlein
J. Wolf
Show All
Source
Cite
Save
Citations (2)
rosette-inhibiting factor L428 cells derived from Hodgkin's disease produce E
2011
I. Katay
U Wirnitzer
H. Burrichter
C. Von Kalle
E. Schell-Frederick
Volker Diehl
M. Schaadt
Show All
Source
Cite
Save
Citations (0)
SORAVE trial: Phase I sorafenib and everolimus in solid tumors.
2010
Journal of Clinical Oncology
Lucia Nogova
Matthias Scheffler
Irini Papachristou
Christian Mattonet
R. Krais
I. Katay
Peter Mallmann
Uwe Fuhr
Markus Dietlein
J. Wolf
Show All
Source
Cite
Save
Citations (0)
Apoptosis in freshly isolated leukemia cells from patients with acute myeloblastic leukemia cells from patients with acute myeloblastic leukemia and chronic lymphocytic leukemia induced by cytotoxic anticancer drugs in relation to clinical response to chemotherapy
1996
D. Segat
Christoph Scheid
A Schulz
S. Winter
Andreas Josting
I. Katay
V Diehl
P. D. as Wickramanayake
Show All
Source
Cite
Save
Citations (0)
Rosette inhibiting factor (RIF) produced by Hodgkin-cell lines
1986
Journal of Cancer Research and Clinical Oncology
I. Katay
E. Zittlau
H. Burrichter
Michael Schaadt
Volker Diehl
Show All
Source
Cite
Save
Citations (0)
1